In a report released on January 5, Julian Harrison from BTIG maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $1.48.
According to TipRanks, Harrison is a 5-star analyst with an average return of 12.9% and a 52.03% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Viridian Therapeutics, and CymaBay Therapeutics.
Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.33.
See today’s best-performing stocks on TipRanks >>
AKBA market cap is currently $278.8M and has a P/E ratio of -4.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics (AKBA) Company Description:
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Read More on AKBA:
